NEWS: PR campaign to boost new heart failure treatment

A drug claimed to improve the condition of patients suffering from heart failure is to get the backing of a PR campaign from joint marketers SmithKline Beecham and Boehringer Mannheim UK.

A drug claimed to improve the condition of patients suffering from heart

failure is to get the backing of a PR campaign from joint marketers

SmithKline Beecham and Boehringer Mannheim UK.



The two pharmaceutical firms are poised to appoint a PR agency this week

to handle an educational campaign for Carvedilol, a beta blocker

normally prescribed for hypertension. Hill and Knowlton and Advisa

Medica have been shortlisted for the account, believed to be worth

pounds 60,000 in fees.



The winning agency will target cardiologists and GPs to explain the use

of Carvedilol, which has been tested in patient trials by SB and

Boehringer Mannheim since the 1980’s. Phase two of the campaign,

beginning next year, will target the public with the message that there

is a treatment available.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in